JP2010523716A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010523716A5 JP2010523716A5 JP2010503256A JP2010503256A JP2010523716A5 JP 2010523716 A5 JP2010523716 A5 JP 2010523716A5 JP 2010503256 A JP2010503256 A JP 2010503256A JP 2010503256 A JP2010503256 A JP 2010503256A JP 2010523716 A5 JP2010523716 A5 JP 2010523716A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- benzodiazepine
- flumazenil
- bretazenil
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 24
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical group C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 claims 8
- 229960004381 flumazenil Drugs 0.000 claims 8
- 239000004480 active ingredient Substances 0.000 claims 6
- 239000000749 benzodiazepine receptor blocking agent Substances 0.000 claims 6
- 229950010832 bretazenil Drugs 0.000 claims 6
- LWUDDYHYYNNIQI-ZDUSSCGKSA-N bretazenil Chemical group O=C1C2=C(Br)C=CC=C2N2C=NC(C(=O)OC(C)(C)C)=C2[C@@H]2CCCN21 LWUDDYHYYNNIQI-ZDUSSCGKSA-N 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 5
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 3
- 229940110385 Benzodiazepine receptor antagonist Drugs 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 229940049706 benzodiazepine Drugs 0.000 claims 3
- 239000000759 benzodiazepine receptor stimulating agent Substances 0.000 claims 3
- 241000269435 Rana <genus> Species 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 239000006194 liquid suspension Substances 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 230000006883 memory enhancing effect Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 239000007935 oral tablet Substances 0.000 claims 1
- 239000007944 soluble tablet Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91125407P | 2007-04-11 | 2007-04-11 | |
| PCT/US2008/060133 WO2008128116A1 (en) | 2007-04-11 | 2008-04-11 | Treatment of down syndrome with benzodiazepine receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010523716A JP2010523716A (ja) | 2010-07-15 |
| JP2010523716A5 true JP2010523716A5 (enExample) | 2011-05-26 |
Family
ID=39864354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010503256A Pending JP2010523716A (ja) | 2007-04-11 | 2008-04-11 | ベンゾジアゼピン受容体拮抗薬を用いるダウン症候群の治療 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2146576A4 (enExample) |
| JP (1) | JP2010523716A (enExample) |
| AU (1) | AU2008240148B2 (enExample) |
| CA (1) | CA2683754A1 (enExample) |
| WO (1) | WO2008128116A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012114342A1 (en) | 2011-02-23 | 2012-08-30 | Coeruleus Ltd. | Flumazenil complexes, compositions comprising same and uses thereof |
| CN112569216B (zh) * | 2019-09-30 | 2022-02-15 | 厦门大学 | 戊酸衍生物在治疗唐氏综合征中的应用 |
| GB202413915D0 (en) * | 2024-09-20 | 2024-11-06 | Fitabeo Therapeutics Ltd | treatment of drug use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6297256B1 (en) * | 1999-06-15 | 2001-10-02 | Neurogen Corporation | Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands |
| ES2278345T3 (es) * | 2003-07-25 | 2007-08-01 | Neurogen Corporation | Imidazo-pirimidinas y triazolo-pirimidinas: ligandos de receptores de benzodiazepinas. |
| US20070078083A1 (en) * | 2005-09-07 | 2007-04-05 | Braincells, Inc. | MODULATION OF NEUORGENESIS BY HDac INHIBITION |
-
2008
- 2008-04-11 JP JP2010503256A patent/JP2010523716A/ja active Pending
- 2008-04-11 CA CA002683754A patent/CA2683754A1/en not_active Abandoned
- 2008-04-11 EP EP08745691A patent/EP2146576A4/en not_active Withdrawn
- 2008-04-11 AU AU2008240148A patent/AU2008240148B2/en not_active Expired - Fee Related
- 2008-04-11 WO PCT/US2008/060133 patent/WO2008128116A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009525343A5 (enExample) | ||
| JP2005512995A5 (enExample) | ||
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| JP2009510171A5 (enExample) | ||
| CA2671954A1 (en) | Methods for treating or preventing symptoms of hormonal variations | |
| SI2529622T1 (en) | Inhibitors of bruton's tyrosine kinase | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| FI2498756T4 (fi) | Neratinibimaleaatin tablettiformulaatiot | |
| WO2008040534A3 (en) | Non-mucoadhesive film dosage forms | |
| PL2063861T3 (pl) | Jednostka dawkowania do podawania podjęzykowego, podpoliczkowego lub doustnego nierozpuszczalnych w wodzie substancji aktywnych farmaceutycznie | |
| JP2009522370A5 (enExample) | ||
| HRP20160189T1 (hr) | Liječenje crohnove bolesti lakvinimodom | |
| HRP20180942T1 (hr) | Liječenje negativnih simptoma shizofrenije s (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamidom i njegovim farmaceutski prihvatljivim solima | |
| CL2014001029A1 (es) | Forma de dosificacion farmaceutica solida oral de liberacion extendida que comprende una formulacion matricial que comprende un agente activo en forma de comprimido o multiparticulado; agente activo es un analgesico opioide; y uso en el tratamiento del dolor. (div. sol. 499-2012). | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| AR068947A1 (es) | Inhibidor de la proteina activadora de la 5- lipoxigenasa (flap), composiciones farmaceuticas, sales y solvatos | |
| HRP20171743T1 (hr) | Sastavi i postupci za savladavanje otpornosti na tramadol | |
| JP2010522137A5 (enExample) | ||
| UA116334C2 (uk) | Тверді форми дозування бендамустину | |
| WO2010092450A8 (en) | Stable pharmaceutical composition for atherosclerosis | |
| WO2008084504A3 (en) | Pharmaceutical compositions of angiotensin ii receptor blockers | |
| JP2008533142A (ja) | α７ニューロンニコチン性受容体リガンドおよび抗精神病薬組成物 | |
| JP2015514739A5 (enExample) | ||
| RU2011152105A (ru) | Составы таблеток 3-цианохинолина и их применение | |
| JP2009518293A5 (enExample) |